A Study Evaluating Topical Recombinant Human Vascular Endothelial Growth Factor (Telbermin) for Induction of Healing of Chronic, Diabetic Foot Ulcers
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00069446|
Recruitment Status : Completed
First Posted : September 26, 2003
Last Update Posted : May 11, 2017
|Condition or disease||Intervention/treatment||Phase|
|Foot Ulcer||Drug: rhuMAb VEGF (telbermin)||Phase 1|
|Study Type :||Interventional (Clinical Trial)|
|Enrollment :||50 participants|
|Official Title:||An Exploratory, Double-Blind, Randomized, Placebo Controlled Study Evaluating Topical Recombinant Human Vascular Endothelial Growth Factor (Telbermin) for Induction of Healing of Chronic, Diabetic Foot Ulcers|
|Actual Study Start Date :||August 2003|
|Actual Primary Completion Date :||October 2004|
|Actual Study Completion Date :||October 2004|
- Incidence of clinically significant hypotension.
- Incidence of clinically significant ulcer infection defined by increased discharge and malodorous exudates from the ulcer, fever, and a white blood cell (WBC) count of >10,000/uL
- Development of anti telbermin antibodies
- Incidence of adverse events
- Percent reduction in total ulcer surface area.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00069446
|Study Director:||Tim Breen, Ph.D.||Genentech, Inc.|